Considering that FZD10 is specifically upregulated at very high level in synovial sarcoma tissues comparing to most normal organs (except for placenta) [163,164], Fukukawa et al. prepared a murine monoclonal antibody (MAb), MAb 92-13 (1) [164], with specific binding activity against native FZD10 in synovial sarcoma cell lines (Figure 1). Here, FZD10 is linked to synovial sarcoma.